|
Global Hepatitis Summit - Retreatment With Sofosbuvir/Velpatasvir/Voxilaprevir
for 12 Weeks Is Safe and Effective for Patients Who
Have Previously Received Sofosbuvir/Velpatasvir or
Sofosbuvir/Velpatasvir/Voxilaprevir
|
|
|
Reported by Jules Levin
![0618181](../images%20/061818/061818-9/0618181.gif)
Peter Ruane,1 Simone I. Strasser,2 Edward J. Gane,3 Robert H. Hyland,4
Jiang Shao,4 Hadas Dvory-Sobol,4 Tram Tran,4 Luisa M. Stamm,4
Diana M. Brainard,4 Lisa Nyberg,5 Stephen Shafran6
1Ruane Medical & Liver Health Institute, Los Angeles, California, USA;
2AW Morrow Gastroenterology and Liver Centre, Sydney, New South Wales, Australia;
3The University of Auckland, New Zealand; 4Gilead Sciences, Inc., Foster City, California;
5Kaiser Permanente, San Diego, California; 6University of Alberta, Edmonton, Canada
![0618182](../images%20/061818/061818-9/0618182.gif)
![0618183](../images%20/061818/061818-9/0618183.gif)
![0618184](../images%20/061818/061818-9/0618184.gif)
![0618185](../images%20/061818/061818-9/0618185.gif)
![0618186](../images%20/061818/061818-9/0618186.gif)
![0618187](../images%20/061818/061818-9/0618187.gif)
![0618188](../images%20/061818/061818-9/0618188.gif)
![0618189](../images%20/061818/061818-9/0618189.gif)
| |
|
|
|
|
|